Back to Search Start Over

[The French mesothelioma network from 1998 to 2013].

Authors :
Galateau-Sallé F
Gilg Soit Ilg A
Le Stang N
Brochard P
Pairon JC
Astoul P
Frenay C
Blaizot G
Chamming's S
Ducamp S
Rousvoal T
de Quillacq A
Abonnet V
Abdalsamad I
Begueret H
Brambilla E
Capron F
Copin MC
Danel C
de Lajartre AY
Foulet-Roge A
Garbe L
Groussard O
Giusiano S
Hofman V
Lantuejoul S
Piquenot JM
Rouquette I
Sagan C
Thivolet-Bejui F
Vignaud JM
Scherpereel A
Jaurand MC
Jean D
Hainaut P
Chérié-Challine L
Goldberg M
Luce D
Imbernon E
Source :
Annales de pathologie [Ann Pathol] 2014 Feb; Vol. 34 (1), pp. 51-63. Date of Electronic Publication: 2014 Feb 26.
Publication Year :
2014

Abstract

Mesothelioma is a rare disease less than 0.3% of cancers in France, very aggressive and resistant to the majority of conventional therapies. Asbestos exposure is nearly the only recognized cause of mesothelioma in men observed in 80% of case. In 1990, the projections based on mortality predicted a raise of incidence in mesothelioma for the next three decades. Nowadays, the diagnosis of this cancer is based on pathology, but the histological presentation frequently heterogeneous, is responsible for numerous pitfalls and major problems of early detection toward effective therapy. Facing such a diagnostic, epidemiological and medico-legal context, a national and international multidisciplinary network has been progressively set up in order to answer to epidemiological survey, translational or academic research questions. Moreover, in response to the action of the French Cancer Program (action 23.1) a network of pathologists was organized for expert pathological second opinion using a standardized procedure of certification for mesothelioma diagnosis. We describe the network organization and show the results during this last 15years period of time from 1998-2013. These results show the major impact on patient's management, and confirm the interest of this second opinion to provide accuracy of epidemiological data, quality of medico-legal acknowledgement and accuracy of clinical diagnostic for the benefit of patients. We also show the impact of these collaborative efforts for creating a high quality clinicobiological, epidemiological and therapeutic data collection for improvement of the knowledge of this dramatic disease.<br /> (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)

Details

Language :
French
ISSN :
0242-6498
Volume :
34
Issue :
1
Database :
MEDLINE
Journal :
Annales de pathologie
Publication Type :
Academic Journal
Accession number :
24630637
Full Text :
https://doi.org/10.1016/j.annpat.2014.01.009